Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Arch Therapeutics Inc (ARTH)

Arch Therapeutics Inc (ARTH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Arch Therapeutics Inc 235 WALNUT STREET SUITE 6 FRAMINGHAM MA 01702 USA

www.archtherapeutics.com P: 617-431-2313

Description:

Arch Therapeutics, Inc. is a medical device company. It develops products that make surgery and interventional care faster and safer by using an approach to stop bleeding, control leaking, and provide other advantages during surgery and trauma care. The Company's lead product candidate includes AC5 (TM), a biocompatible synthetic peptide, to achieve hemostasis in minimally invasive and open surgical procedures. Arch Therapeutics, Inc. is headquartered in Wellesley, Massachusetts.

Key Statistics

Overview:

Market Capitalization, $K 5,596
Enterprise Value, $K 5,376
Shares Outstanding, K 4,742
Annual Sales, $ 80 K
Annual Net Income, $ -6,980 K
Last Quarter Sales, $ 50 K
Last Quarter Net Income, $ -2,680 K
EBIT, $ -5,260 K
EBITDA, $ -5,260 K
60-Month Beta 3.52
% of Insider Shareholders 4.50%
% of Institutional Shareholders 6.91%
Float, K 4,529
% Float 95.50%
Short Volume Ratio 0.56

Growth:

1-Year Return -60.67%
3-Year Return -95.75%
5-Year Return -98.29%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.57 on 02/20/24
Latest Earnings Date 05/28/24
Earnings Per Share ttm -1.78
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-200 on 01/18/23

ARTH Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % -386.74%
Profit Margin % -8,725.00%
Debt/Equity 0.00
Price/Sales 71.40
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -2.02
Interest Coverage -1.25
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar